Navigation Links
Cellix Ltd. Launches the First Semi-Automated, High Throughput Cell-Adhesion Assay Platform
Date:1/28/2008

The VenaFlux(TM) Platform Accurately Mimics a Human Capillary

DUBLIN, Ireland, Jan. 28 /PRNewswire/ -- Cellix Ltd., an international provider of microfluidic systems in the emerging field of nano-lifesciences, announced today its worldwide launch of its VenaFlux(TM) Platform. The VenaFlux(TM), the first semi-automated, high throughput microfluidic cell- based assay system, measures cell adhesion to antibody-coated or endothelial- cell cultured microchannels, producing IC50 curves under shear stress conditions mimicking physiological flow. The system thereby offers scientists an important and unique tool for drug discovery. The VenaFlux(TM) is simple to use, reduces costly layers of animal model studies, and delivers specific, accurate, and reproducible results.

Using the VenaFlux(TM), scientists can rapidly obtain quantitative analyses and results for potential drug candidates in therapeutic areas including cardiovascular, respiratory, immunologic, autoimmune and oncologic disease states. Relatively rapid analyses reduces drug development costs by accelerating false lead elimination and increasing productivity in pharmaceutical and biotechnology research and development laboratories.

"Understanding how cells behave in human capillaries is an expanding area in global research and development for discovering new patient therapies," said Vivienne Williams, CEO of Cellix Ltd. "Our VenaFlux(TM) accurately replicates cell behavior in human capillaries, an in vitro modeling system that has previously been difficult to achieve.

Cellix's technology provides researchers with a single platform for executing dynamic studies to analyze the effects of drugs on cell adhesion, proliferation and transmigration under well-defined shear stress protocols that replicate physiological conditions. "To date, pharmaceutical companies including AstraZeneca and Amgen, as well as research institutions such as the US National Institutes of Health have adopted Cellix's technology to characterize drug effects," commented Ms. Williams.

About the VenaFlux Platform

The VenaFlux(TM) Platform consists of Cellix's patented Mirus(TM) Nanopump with VenaFluxAssay(TM) software, Vena8(TM) Biochips and DucoCell(TM) analysis software; Carl Zeiss Axiovert(TM) 40 CFL microscope, motorized stage with Z- focus, microscope cage incubator, automated dispenser arm, digital camera for image acquisition and PC. The VenaFlux(TM) Platform can run 8 microcapillaries in 15 minutes, thereby achieving 32 assays in one hour or approximately 1,000 assays per week. The VenaFlux(TM) Platform provides an important new in vitro alternative to expensive animal models while simultaneously cutting down costs on reagents and manpower.

About Cellix Ltd.

Cellix Ltd. is a privately held instrumentation and cell-based assay company developing technologies that accurately mimic cellular behavior in vivo for cell-based screening in drug discovery. The Company is headquartered in Dublin, Ireland, and maintains offices in New York City. For further information visit http://www.cellixltd.com


'/>"/>
SOURCE Cellix Ltd.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Decision Biomarkers Launches System for Faster, Easier Quantification of Protein Biomarkers
2. PennWell Launches Bio-Optics World Magazine and Web Site
3. DRI Capital Launches Structured Finance Fund
4. Rosetta Genomics Announces Initiation of Expansion of US Operations to Facilitate Expected Product Launches in 2008
5. LineaGen Inc. Launches With Close of $5.8 Million Series A Funding Round
6. SleepQuest Launches Updated Web Site
7. Bradley Pharmaceuticals Launches Veregen(TM) (sinecatechins) Ointment, 15%
8. DeviceSpace.com Launches Marketing Campaign for US Medical Device Industry
9. Video and Photo: EMD Serono Launches easypod(R), New Electronic Growth Hormone Injection Device
10. Vical Launches Redesigned Website
11. BioSpace Launches 3rd Edition of BioForest(TM) Bioscience Marketing Campaign
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/10/2017)... (PRWEB) , ... October 10, 2017 , ... ... Science Center’s FirstHand program has won a US2020 STEM Mentoring Award. Representatives of ... award for Excellence in Volunteer Experience from US2020. , US2020’s mission is to ...
(Date:10/10/2017)... , Oct. 10, 2017 SomaGenics announced ... the NIH to develop RealSeq®-SC (Single Cell), expected to ... profiling small RNAs (including microRNAs) from single cells using ... highlights the need to accelerate development of approaches to ... "New techniques for measuring levels of ...
(Date:10/9/2017)...  BioTech Holdings announced today identification and patenting ... stem cell therapy prevents limb loss in animal ... that treatment with ProCell resulted in more than ... to standard bone marrow stem cell administration.  Interestingly, ... of therapeutic effect.  ...
(Date:10/9/2017)... ... October 09, 2017 , ... The ... medical marijuana products targeting the needs of consumers who are incorporating medical marijuana ... place in Phoenix, Arizona. , As operators of two successful Valley dispensaries, The ...
Breaking Biology Technology:
(Date:4/6/2017)... , April 6, 2017 ... RFID, ANPR, Document Readers, by End-Use (Transportation & Logistics, ... Facility, Oil, Gas & Fossil Generation Facility, Nuclear Power), ... Educational, Other) Are you looking for a ... sector? ...
(Date:4/4/2017)...   EyeLock LLC , a leader of iris-based ... Patent and Trademark Office (USPTO) has issued U.S. Patent ... an iris image with a face image acquired in ... 45 th issued patent. "The ... the multi-modal biometric capabilities that have recently come to ...
(Date:3/30/2017)... , March 30, 2017 Trends, opportunities ... (physiological and behavioral), by technology (fingerprint, AFIS, iris recognition, ... recognition, and others), by end use industry (government and ... immigration, financial and banking, and others), and by region ... , Asia Pacific , and ...
Breaking Biology News(10 mins):